

Client: Example Client ABC123
123 Test Drive
Salt Lake City, UT 84108
UNITED STATES

Physician: Doctor, Example

Patient: Patient, Example

DOB: 4/24/1974
Gender: Male
Patient Identifiers: 01234567890ABCD, 012345
Visit Number (FIN): 01234567890ABCD
Collection Date: 00/00/0000 00:00

Human Immunodeficiency Virus 1, Genotype by Sequencing

ARUP test code 0055670

HIV-1 Genotype by Sequencing

See Note

Drug Resistance:
NRTI Drug Class

VIDEX, (didanosine, ddI)	None
VIREAD, (tenofovir, TDF)	None
ZERIT, (stavudine, d4T)	None
ZIAGEN, (abacavir, ABC)	None
EMTRIVA, (emtricitabine, FTC)	None
RETROVIR, (zidovudine, ZDV)	None
EPIVIR, (lamivudine, 3TC)	None

NRTI drug resistance mutations identified: None

NNRTI Drug Class

SUSTIVA, (efavirenz, EFV)	Possible Resistance*
VIRAMUNE, (nevirapine, NVP)	Resistance*
INTELENCE, (etravirine, ETR)	Possible Resistance*
EDURANT, (rilpivirine, RPV)	Possible Resistance*

NNRTI drug resistance mutations identified: K101E,
Y181C

PI+ Drug Class

VIRACEPT, (nelfinavir, NFV)	None
APTIVUS, (tipranavir, TPV)	None
CRIXIVAN, (indinavir, IDV)	None
KALETRA, (lopinavir + ritonavir, LPV)	None
REYATAZ, (atazanavir, ATV)	None
PREZISTA, (darunavir, DRV)	None
LEXIVA, (fosamprenavir, FPV)	None
FORTOVASE / INVIRASE, (saquinavir, SQV)	None

PI+ drug resistance mutations identified: A71T

Additional Mutations: The following amino acids differing from the reference sequence (HXB-2, accession number K03455) at the indicated codon positions were identified and may be useful as a baseline determination of virus genotype.

Protease: V3I, S37N, R57K, L63P, V77I
RT: V35T, S48E, E122K, D123N, I135V, S162C, Q174H,
I178L, T200A, R211K, L214F, V245E, R277K, I293V, E297A,
L310I, K311R, G333E, Q334N, G335S

+ Evidence of Resistance for Protease Inhibitors estimates response to ritonavir boosted regimens. Refer to "Evidence of Resistance Legend." The protease inhibitor (PI) evidence of resistance interpretations

H=High, L=Low, *=Abnormal, C=Critical

were developed to estimate the expected virological response to standard doses of protease inhibitors with pharmacokinetic boosting by ritonavir. This has become the most common method of administering each of the protease inhibitors, except nelfinavir (ref. 1), to ensure adequate drug levels in all patients. Boosted PIs are more active in the presence of resistance than nonboosted PIs(ref. 2,3)

* NOTE: At least one mutation used to determine Evidence of Resistance for this drug has not been fully validated.

Evidence of Resistance Legend:

Resistance: Mutations present constitute a high level of genetic evidence for viral resistance.

Possible Resistance: Mutations present suggest the possibility of viral resistance.

None: There is insufficient evidence for viral resistance.

Software Version: ViroSeq HIV-1 System v2.0; ViroSeq Software v3.0

INTERPRETIVE INFORMATION: HIV-1 Genotyping

This assay predicts HIV-1 resistance to protease and reverse transcriptase inhibitor anti-retroviral drugs. The protease gene and codons 1-335 of the reverse transcriptase gene of the viral genome are sequenced using the Viroseq HIV-1 Genotyping System kit. Drug resistance is assigned using ViroSeq software. The most current resistance algorithm and drug list is available by selecting the Drug Resistance Report found in the test directory.

This test should be used in conjunction with clinical presentation and other laboratory markers. A patient's response to therapy depends on multiple factors, including patient compliance, percentage of resistant virus population, dosing, and drug pharmacology issues. Resistance interpretations may vary with methodology.

Some insertions or deletions may be difficult to detect using this software. This test may not detect minor HIV-1 populations less than 20 percent of the total population.

Test developed and characteristics determined by ARUP Laboratories. See Compliance Statement B: aruplab.com/CS

EER HIV-1 Genotype by Sequencing

See Note

Access ARUP Enhanced Report using the link below:

-Direct access: [REDACTED]

H=High, L=Low, *=Abnormal, C=Critical

VERIFIED/REPORTED DATES				
Procedure	Accession	Collected	Received	Verified/Reported
HIV-1 Genotype by Sequencing	20-286-133576	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
EER HIV-1 Genotype by Sequencing	20-286-133576	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00

END OF CHART

H=High, L=Low, *=Abnormal, C=Critical

Unless otherwise indicated, testing performed at:

ARUP LABORATORIES | 800-522-2787 | aruplab.com
500 Chipeta Way, Salt Lake City, UT 84108-1221
Tracy I. George, MD, Laboratory Director

Patient: Patient, Example
ARUP Accession: 20-286-133576
Patient Identifiers: 01234567890ABCD, 012345
Visit Number (FIN): 01234567890ABCD
Page 3 of 3 | Printed: 10/19/2020 12:42:01 PM
4848